Unit Biotech & ATMP’s

GMP facility for the production of investigational drugs based on biotechnological processes and cellular therapies. Facility

GMP facility for the production of investigational drugs based on biotechnological processes and cellular therapies.

The Unit Biotech & ATMP’s is expert in the translation of new innovative drugs into a GMP production process. It manufactures Active Pharmaceutical Ingredients (APIs) and finished Investigational Medicinal Products (IMPs) in accordance with the GMP legislation.

The Unit Biotech & ATMP’s facilitates technical transfer and small-scale production based on biotechnological processes and the production of ATMPs (Advanced Therapy Medicinal Products). ATMPs are medicinal products based on genes, cells and/or tissues.
The facility produces different types of biologicals:

Recombinant proteins from bacterial or yeast cell lines;
Medicinal products based on cells or tissues;
Fluorescent labels for antibodies to be used in imaging studies.

The Unit Biotech & ATMP’s produces biologicals and cell-based products for research groups at the University Medical Center Groningen (UMCG) and the University of Groningen (UG), academic hospitals, and companies that focus on the development and production of biotechnological drugs or ATMPs.
The Unit Biotech & ATMP’s provides researchers with support in translating their preclinical findings into a process that meets the GMP standards.